Download PDF
Digestive Disease Interventions 2021; 05(04): 346-350
DOI: 10.1055/s-0041-1736411
Review Article

Role of SCO-792, A Novel Enteropeptidase Inhibitor, In the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis

Mohammed Yousif Rashid
1   California Institute of Behavioral Neurosciences and Psychology, Family Medicine, Fairfield, California
,
Anupa Gnawali
1   California Institute of Behavioral Neurosciences and Psychology, Family Medicine, Fairfield, California
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Acute pancreatitis is the most common iatrogenic dilemma of endoscopic retrograde cholangiopancreatography, and it is associated with significant morbidity and mortality. Several factors have been implicated in the pathogenesis of post-endoscopic retrograde cholangiopancreatography pancreatitis, and preventive measures were practiced accordingly. This study aims to refine the potential mechanisms that trigger post-endoscopic retrograde cholangiopancreatography pancreatitis and define the role of enteropeptidase in the pathogenesis of post-endoscopic retrograde cholangiopancreatography pancreatitis. Furthermore, address the role of a new novel medication known as SCO-792, a potent enteropeptidase inhibitor, in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis.

Post-endoscopic retrograde cholangiopancreatography pancreatitis is caused by premature activation of the pancreatic enzymes within the pancreatic parenchyma. This activation is either an autoactivation due to direct provocation of intra-acinar enzymes as a result of the procedure or due to activation by enterpeptidase, a rate-limiting enzyme. Endoscopic retrograde cholangiopancreatography interjects duodenal juice that is rich in enterokinase into the pancreatic-biliary tract, which in turn leads to intra-ductal activation of trypsinogen and subsequent enzymes. Given the vital role of enterokinase in initiating the pathogenesis of pancreatitis, enteropeptidase inhibition may prevent and reduce the severity of post-endoscopic retrograde cholangiopancreatography pancreatitis.

SCO-792, a novel enteropeptidase inhibitor, is developed by SCOHIA Pharma, and pre-clinical trials confirmed its efficacy in inhibiting enteropeptidase. Studies are needed to confirm the efficacy of enteropeptidase inhibitors in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.

Keywords

pancreatitis - ERCP - post-ERCP pancreatitis - enteropeptidase - SCO-792


Publication History

Received: 23 January 2021

Accepted: 24 August 2021

Article published online:
06 October 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Freeman ML, Nelson DB, Sherman S. et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335 (13) 909-918
    CrossrefPubMedSearch in Google Scholar
  • 2 Cheon YK, Cho KB, Watkins JL. et al. Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification. Gastrointest Endosc 2007; 65 (03) 385-393
    CrossrefPubMedSearch in Google Scholar
  • 3 Testoni PA. Why the incidence of post-ERCP pancreatitis varies considerably? Factors affecting the diagnosis and the incidence of this complication. JOP 2002; 3 (06) 195-201
    PubMedSearch in Google Scholar
  • 4 Mann N, Mann S. : Enterokinase. Exp Biol Med. 1994; 206: 114-118 . Doi: 10.3181%2F00379727–206–43728
    CrossrefPubMedSearch in Google Scholar
  • 5 Zheng XL, Kitamoto Y, Sadler JE. Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed) 2009; 1: 242-249
    PubMedSearch in Google Scholar
  • 6 Light A, Janska H. Enterokinase (enteropeptidase): comparative aspects. Trends Biochem Sci 1989; 14 (03) 110-112
    CrossrefPubMedSearch in Google Scholar
  • 7 Abita JP, Delaage M, Lazdunski M, Savrda J. The mechanism of activation of trypsinogen. The role of the four N-terminal aspartyl residues. Eur J Biochem 1969; 8 (03) 314-324
    CrossrefPubMedSearch in Google Scholar
  • 8 Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc 2004; 59 (07) 845-864
    CrossrefPubMedSearch in Google Scholar
  • 9 Christoforidis E, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis D. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy 2002; 34 (04) 286-292
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Rabenstein T, Schneider HT, Bulling D. et al. Analysis of the risk factors associated with endoscopic sphincterotomy techniques: preliminary results of a prospective study, with emphasis on the reduced risk of acute pancreatitis with low-dose anticoagulation treatment. Endoscopy 2000; 32 (01) 10-19
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Freeman ML, DiSario JA, Nelson DB. et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001; 54 (04) 425-434
    CrossrefPubMedSearch in Google Scholar
  • 12 Loperfido S, Angelini G, Benedetti G. et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48 (01) 1-10
    CrossrefPubMedSearch in Google Scholar
  • 13 Vandervoort J, Soetikno RM, Tham TC. et al. Risk factors for complications after performance of ERCP. Gastrointest Endosc 2002; 56 (05) 652-656
    CrossrefPubMedSearch in Google Scholar
  • 14 Ogura T, Imoto A, Okuda A, Fukunishi S, Higuchi K. Can iodixanol prevent post-endoscopic retrograde cholangiopancreatography pancreatitis? A prospective, randomized, controlled trial. Dig Dis 2019; 37 (03) 255-261
    CrossrefPubMedSearch in Google Scholar
  • 15 Andriulli A, Clemente R, Solmi L. et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002; 56 (04) 488-495
    CrossrefPubMedSearch in Google Scholar
  • 16 Lin Y, Liu X, Cao DQ. et al. Analysis of risk factors and prevention strategies of post-ERCP pancreatitis. Eur Rev Med Pharmacol Sci 2017; 21 (22) 5185-5190
    CrossrefPubMedSearch in Google Scholar
  • 17 Cheng CL, Sherman S, Watkins JL. et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol 2006; 101 (01) 139-147
    CrossrefPubMedSearch in Google Scholar
  • 18 Koike H, Steer ML, Meldolesi J. Pancreatic effects of ethionine: blockade of exocytosis and appearance of crinophagy and autophagy precede cellular necrosis. Am J Physiol 1982; 242 (04) G297-G307
    CrossrefPubMedSearch in Google Scholar
  • 19 Watanabe O, Baccino FM, Steer ML, Meldolesi J. Supramaximal caerulein stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol 1984; 246 (4 Pt 1): G457-G467
    CrossrefPubMedSearch in Google Scholar
  • 20 Saluja A, Hashimoto S, Saluja M, Powers RE, Meldolesi J, Steer ML. Subcellular redistribution of lysosomal enzymes during caerulein-induced pancreatitis. Am J Physiol 1987; 253 (4 Pt 1): G508-G516
    CrossrefPubMedSearch in Google Scholar
  • 21 Saito I, Hashimoto S, Saluja A, Steer ML, Meldolesi J. Intracellular transport of pancreatic zymogens during caerulein supramaximal stimulation. Am J Physiol 1987; 253 (4 Pt 1): G517-G526
    CrossrefPubMedSearch in Google Scholar
  • 22 Greenbaum LM, Hirshkowitz A. Endogenous cathepsin activation of trypsinogen in extracts of dog pancreas. Proc Soc Exp Biol Med 1961; 107: 74-76
    CrossrefPubMedSearch in Google Scholar
  • 23 Mann NS. Effect of intraductal enterokinase, 5-azacytidine and cycloheximide on pancreatic protein content. Am J Proctol Gastroenterol Colon Rectal Surg 1980; 31 (09) 15-16 , 21
    PubMedSearch in Google Scholar
  • 24 Hammond JB, Mann NS. Pancreatitis following the intraductal injection of partially purified enterokinase in dogs. Am J Dig Dis 1977; 22 (03) 182-188
    CrossrefPubMedSearch in Google Scholar
  • 25 Mann NS, Kadian RS, Narenderan K. Enterokinase induced pancreatitis: its prevention with Trasylol and soybean trypsin inhibitor. Am J Proctol Gastroenterol Colon Rectal Surg 1978; 29 (06) 13-17
    PubMedSearch in Google Scholar
  • 26 Sasaki M, Miyahisa I, Itono S. et al. Discovery and characterization of a small-molecule enteropeptidase inhibitor, SCO-792. Pharmacol Res Perspect 2019; 7 (05) e00517
    CrossrefPubMedSearch in Google Scholar
  • 27 Zamolodchikova TS, Sokolova EA, Lu D, Sadler JE. Activation of recombinant proenteropeptidase by duodenase. FEBS Lett 2000; 466 (2-3): 295-299
    CrossrefPubMedSearch in Google Scholar
  • 28 Hadorn B, Tarlow MJ, Lloyd JK, Wolff OH. Intestinal enterokinase deficiency. Lancet 1969; 1 (7599): 812-813
    CrossrefPubMedSearch in Google Scholar
  • 29 Holzinger A, Maier EM, Bück C. et al. Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency. Am J Hum Genet 2002; 70 (01) 20-25
    CrossrefPubMedSearch in Google Scholar
  • 30 Braud S, Ciufolini MA, Harosh I. Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment. PLoS One 2012; 7 (11) e49612
    CrossrefPubMedSearch in Google Scholar
  • 31 Katayama Y, Sugama J, Suzuki T. et al. Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease. Nephrol Dial Transplant 2020; 1-9
    CrossrefPubMedSearch in Google Scholar
  • 32 Gasparian ME, Ostapchenko VG, Dolgikh DA, Kirpichnikov MP. Biochemical characterization of human enteropeptidase light chain. Biochemistry (Mosc) 2006; 71 (02) 113-119
    CrossrefPubMedSearch in Google Scholar